ZVSA icon

ZyVersa Therapeutics

0.6099 USD
-0.0605
9.02%
At close Apr 30, 4:00 PM EDT
Pre-market
0.6099
+0.0000
0.00%
1 day
-9.02%
5 days
-17.47%
1 month
-2.97%
3 months
-55.80%
6 months
-69.66%
Year to date
-44.05%
1 year
-88.47%
5 years
-99.98%
10 years
-99.98%
0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,094% more capital invested

Capital invested by funds: $7.22K [Q3] → $86.2K (+$79K) [Q4]

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

33% more funds holding

Funds holding: 6 [Q3] → 8 (+2) [Q4]

7.29% more ownership

Funds ownership: 0.29% [Q3] → 7.58% (+7.29%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for ZVSA.

Financial journalist opinion

Based on 3 articles about ZVSA published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease
ZyVersa's IC 100 blocked microglial NLRP1 inflammasome activation and reduced alpha-synuclein accumulation supporting its potential for Parkinson's Disease
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease
Neutral
GlobeNewsWire
6 days ago
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status
Inflammasome inhibitors have moved into P2 trials based on preclinical/P1 safety data & promising signals of efficacy. Data read-outs expected beginning H1
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status
Neutral
GlobeNewsWire
3 weeks ago
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)
WESTON, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen C.
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)
Neutral
GlobeNewsWire
1 month ago
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS: Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR 200's lead indication, focal segmental glomerulosclerosis (FSGS), expected to be shorter based on FDA's alignment with data supporting proteinuria reduction as a clinical trial endpoint for approval of FSGS drugs (Parasol Initiative).
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Neutral
GlobeNewsWire
1 month ago
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
Inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function in obesity-associated cardiomyopathy.
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
Neutral
GlobeNewsWire
1 month ago
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model
WESTON, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights newly published data demonstrating that NLRP3 Inhibition attenuates development of AD pathology (buildup of Aβ) and neuroinflammation in a mouse model of AD, thereby attenuating disease progression.
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model
Neutral
GlobeNewsWire
1 month ago
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
WESTON, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, today announced that it has entered into a securities purchase agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 2,105,265 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,105,265 shares of common stock at an effective combined price of $0.95 per share and common warrant for aggregate gross proceeds of approximately $2.0 million, before deducting placement agent fees and other offering expenses.
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
Neutral
GlobeNewsWire
1 month ago
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
Heart failure with preserved ejection fraction (HFpEF), a chronic inflammatory condition, is a leading cause of morbidity and mortality globally. Obesity, diabetes, and hypertension are highly prevalent in this population and usually precede HFpEF development.
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
Neutral
GlobeNewsWire
4 months ago
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco
ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco
Neutral
GlobeNewsWire
5 months ago
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Charts implemented using Lightweight Charts™